Epitope landscape in breast and colorectal cancer

Cancer Research

Volumn 68, Issue 3, 2008, Pages 889-892

  Segal, Neil H ^a   Parsons, D Williams ^b   Peggs, Karl S ^a   Velculescu, Victor ^b   Kinzler, Ken W ^b   Vogelstein, Bert ^b   Allison, James P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; PEPTIDE;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CARCINOGENESIS; COLORECTAL CANCER; COMPUTER MODEL; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MISSENSE MUTATION; PEPTIDE ANALYSIS; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ALGORITHMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EPITOPES; HLA-A ANTIGENS; HUMANS; MUTATION, MISSENSE;

EID: 38849151665     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3095     Document Type: Article

References (26)

1. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
3. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7.
4. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914-8.
5. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
6. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-93.
7. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78.
8. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960;20:1561-72.
9. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974;53:1333-6.
10. Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983;304:165-7.
11. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
12. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.
13. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
14. Hakenberg J, Nussbaum AK, Schild H, et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics 2003;2:155-8.
15. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
16. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
17. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidatepeptides to HLA-A*0201 molecules. Leuk Res 2006;30:1293-8.
18. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40.
19. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002;63:701-9.
20. Buus S, Lauemoller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a "Query by Committee" artificial neural network approach. Tissue Antigens 2003;62:378-84.
21. Nielsen M, Lundegaard C, Worning P, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003;12:1007-17.
22. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001;62:1009-30.
23. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001;53:87-94.
24. Kuttler C, Nussbaum AK, Dick TP, Rammensee HG, Schild H, Hadeler KP. An algorithm for the prediction of proteasomal cleavages. J Mol Biol 2000;298:417-29.
25. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
26. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90:297-339.